Advance Research, Early Detection and Treatment for Rare Tumors

photo home 1

photo home 2

photo home 3

Welcome to the International Ovarian and Testicular Stromal Tumor Registry. The Registry collects clinical and biologic information about ovarian and testicular stromal tumors in hopes of learning more about treatment of these rare tumors.

Happy Two-Year Anniversary International OTST Registry

January 2014 Blog: Testicular Tumors

Although most participants in the OTST Registry so far have a diagnosis of ovarian stromal tumor, the Registry is also studying testicular stromal tumors. We are working closely with Dr. Nicholas Cost, a pediatric urologist from Colorado Children’s Hospital to study testicular tumors. Please join us in welcoming Dr. Cost to the OTST Blog.

Testicular Stromal Tumor Blog Post

“Study on Clinical and Pathologic Risk Factors in Stage I Testicular Stromal Tumors”

            Testicular stromal tumors are rare (3-5% of all testicular tumors) and include the following subtypes: Leydig cell tumors, Sertoli Cell Tumors, Granulosa Cell Tumors, Mixed Tumors, and Unclassified Stromal Tumors. Overall, most testicular stromal tumors (90%) will present with clinically localized disease (Stage I), confined to the testicle alone. However, up to 10% are malignant and either present with metastasis or will relapse while on surveillance after orchiectomy (removal of the testis) for what was presumed to be Stage I disease.

Given that 90% of testicular stromal tumors are Stage I, the question that troubles the majority of patients and doctors is how to ideally manage those who initially appear to be cured by simply removing of the testicular tumor? Clearly, treating every Stage I patient with additional surgery or chemotherapy to prevent future recurrence would expose up to 90% of patients to unnecessary therapy. However, there may be a threshold of risk that would make such “prophylactic” treatment worth the potential side-effects. In an ideal world, we would identify which clinical and pathologic criteria would predispose the Stage I patients to later recurrence. Previous investigations have identified that some pathologic information from the testicular tumor can indicate an increased risk for later relapse. 

This existing data is unquestionably important, but only serves as a starting point since we still do not understand how much risk each of these features pose and if they act cumulatively such that more “risk factors” places a patient at more risk for recurrence. We have now started a study designed to review all known published literature of patients with Stage I testicular stromal tumors.  These cases will be reviewed to collect data on the presence or absence of the risk factors and other clinical and pathologic features. We will then compare the cases which did or did not experience disease relapse and analyze which of these risk factors are associated with recurrence and try to determine how much risk is associated with each factor.

If you are interested in learning more about this study of testicular stromal tumors, please contact us. Thank you in advance for your interest in understanding how to best treat patients with these rare tumors!

To support the International Ovarian and Testicular Stromal Tumor Registery, please use the DONATE NOW button.